Conclusions
advanced/metastatic gastric/GEJ cancers, gastric/GEJ cancer
CPS, METASTATIC GASTRIC CANCER
These data in Japanese patients indicate that pembrolizumab monotherapy provides consistent survival benefit and an acceptable safety profile when used in the first-line (KEYNOTE-062), second-line (KEYNOTE-061), or third-line or later (KEYNOTE-059) settings in patients with advanced/metastatic gastric/GEJ cancers. The current analysis provides valuable insight and information that anti–PD-1 therapies are worthy of further assessment, particularly in patients with locally advanced/unresectable or metastatic gastric cancer. Furthermore, PD-L1 CPS ≥ 1 can be used as a predictive biomarker of response to pembrolizumab monotherapy; increasing this cutoff to CPS ≥ 10 has the potential to improve patient selection. Adequately powered, prospective clinical trials are needed to validate the optimal use of CPS as a predictive biomarker for patients with gastric/GEJ cancer.